Pune : The Drugs Controller General of India (DGCI) doctor VG Somani on Tuesday cleared the Serum Institute of India (SII) to resume the trial of Oxford-AstraZeneca COVID-19 Vaccine. DCGI has rescinded its earlier order which said to stop second and third stage trials. However, DCGI has laid several other conditions including extra attention during the trial.
Trial was banned in India on September 11
The DGCI has also asked the Serum Institute to submit information about treatment as per rules in dealing with adverse situations. Earlier on September 11, DCGI directed the Serum Institute of India to put a stop to the clinical trial of a possible vaccine for COVID-19 as pharmaceutical giant AstraZeneca reported a health deterioration in one of the countries, after that the trial was stopped.
Trial has started again in Britain, stopped in US
This vaccine is being developed in collaboration with the prestigious Oxford University AstraZeneca company. In India, it has tied up with the Pune-based Serum Institute of India. The trial of this vaccine was resumed in the UK last week. However, the US has stopped its trial on Monday.
Why this vaccine trial was stopped
During the third phase of the vaccine trial, a volunteer had developed a condition of transverse myelitis. There was swelling in the spinal cord that can be caused by infection. More than 50 thousand people worldwide have participated in this phase. After passing the trial in which the vaccine is currently underway, the work of approving the data of safety and impact will remain.
This vaccine may come by the end of this year
AstraZeneca CEO Pascal Soriot expects the vaccine to be available soon. He says that this vaccine may come by the end of this year or early next year. Soriot said that the whole world is eyeing the trial of this vaccine and it is being discussed so much. He hoped that data could be acquired for regulatory approval by the end of the year